Echino_ddPCR: Droplet-digital PCR for the Detection of Circulating Cell-free DNA in Patients With Cystic Echinococcosis: an Exploratory Study

Sponsor
IRCCS Sacro Cuore Don Calabria di Negrar (Other)
Overall Status
Recruiting
CT.gov ID
NCT05769790
Collaborator
(none)
20
2
24.3
10
0.4

Study Details

Study Description

Brief Summary

It is an experimental study, multicentre, non-profit, whose aim is to preliminarily evaluate the sensitivity of ddPCR for the detection of cfDNA in the diagnosis of cystic echinococcosis and to generate data for its potential use also for the discrimination of the presence of infection with active/inactive cysts and the post-therapy follow-up.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: ddPCR
N/A

Detailed Description

It is an experimental study, multicentre, non-profit, whose aim is to preliminarily evaluate the sensitivity of ddPCR for the detection of cfDNA in the diagnosis of cystic echinococcosis and to generate data for its potential also use for discrimination of the presence of infection with active/inactive cysts and follow-up aftercare, to be explored in subsequent studies. For this purpose, the plasma of adult patients with untreated hepatic cystic echinococcosis will be analysed.

The analyzes will be carried out on samples of patients who have already had a definitive diagnosis of cystic echinococcosis, and therefore the results of the study analyzes will have no influence on the diagnosis and clinical management of the patient, which, therefore, will not be informed of the result of the analyzes relating to his/her sample.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Droplet-digital PCR for the Detection of Circulating Cell-free DNA in Patients With Cystic Echinococcosis: an Exploratory Study
Actual Study Start Date :
Mar 21, 2022
Anticipated Primary Completion Date :
Mar 30, 2024
Anticipated Study Completion Date :
Mar 30, 2024

Outcome Measures

Primary Outcome Measures

  1. ddPCR sensitivity [6 months]

    Number of subjects with E. granulosus s.l. cfDNA detected by ddPCR in plasma, in relation to the total number of subjects with certain diagnosis untreated hepatic cystic echinococcosis

Secondary Outcome Measures

  1. ddPCR sensitivity by cyst stage [6 months]

    Number of subjects with cfDNA of E. granulosus s.l. detected by ddPCR in plasma, in ratio to the total number of subjects with certain diagnosis of hepatic cystic echinococcosis not treated divided by the presence of active and inactive cysts.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. age ≥18 years;

  2. definite diagnosis of hepatic cystic echinococcosis, ascertained on the basis of the presence of at least one liver cyst with pathognomonic signs on ultrasound examination or the presence of at least one liver cyst without clearly visible pathognomonic signs but presence of positive serology with at least two validated commercial tests or western blot (LDBIO Diagnostics, Lyon, France) positive for anti-Echinococcus antibodies (WHO-IWGE diagnostic criteria, Brunetti et al 2010);

  3. no prior therapy for cystic echinococcosis reported;

  4. willingness to participate in the study by signing the Informed Consent form.

Exclusion Criteria:
  1. age < 18 years;

  2. unconfirmed diagnosis of cystic echinococcosis; Echino_ddPCR version 1.1 of 02/14/2022

  3. presence of echinococcal cysts only in extra-hepatic localization;

  4. history of treatment for cystic echinococcosis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Fondazione Policlinico San Matteo Pavia PV Italy
2 IRCCS Sacro Cuore Don Calabria hospital Negrar Verona Italy 37024

Sponsors and Collaborators

  • IRCCS Sacro Cuore Don Calabria di Negrar

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
IRCCS Sacro Cuore Don Calabria di Negrar
ClinicalTrials.gov Identifier:
NCT05769790
Other Study ID Numbers:
  • 2022-02
First Posted:
Mar 15, 2023
Last Update Posted:
Mar 15, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2023